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Abstract
Background Surgery for obesity and metabolic diseases has been evolved in the light of new scientific evidence, long-term 
outcomes and accumulated experience. EAES has sponsored an update of previous guidelines on bariatric surgery.
Methods A multidisciplinary group of bariatric surgeons, obesity physicians, nutritional experts, psychologists, anesthetists 
and a patient representative comprised the guideline development panel. Development and reporting conformed to GRADE 
guidelines and AGREE II standards.
Results Systematic review of databases, record selection, data extraction and synthesis, evidence appraisal and evidence-to-
decision frameworks were developed for 42 key questions in the domains Indication; Preoperative work-up; Perioperative 
management; Non-bypass, bypass and one-anastomosis procedures; Revisional surgery; Postoperative care; and Investiga-
tional procedures. A total of 36 recommendations and position statements were formed through a modified Delphi procedure.
and Other Interventional Techniques 
Disclaimer This clinical practice guideline has been developed 
under the auspice of the European Association for Endoscopic 
Surgery (EAES). It is intended to be used primarily by health 
professionals (e.g. surgeons, anesthetists, physicians) and to 
assist in making informed clinical decisions on diagnostic 
measures and therapeutic management. It is also intended to 
inform individual practice of allied health professionals (e.g. 
surgical nurses, dietitians, physical rehabilitation therapists, 
psychologists); to inform strategic planning and resource 
management by healthcare authorities (e.g. regional and national 
authorities, healthcare institutions, hospital administration 
authorities); and to inform patients wishing to obtain an 
overview of the condition of interest and its management. The 
use of recommendations contained herein must be informed by 
supporting evidence accompanying each recommendation and 
by research evidence that might not have been published by the 
time of writing the present document. Users must thus base their 
actions informed by newly published evidence at any given point 
in time. The information in the guideline should not be relied 
upon as being complete or accurate, nor should it be considered 
as inclusive of all proper treatments or methods of care or as a 
statement of the standard of care. With the rapid development 
of scientific knowledge, new evidence may emerge between 
the time the guideline is developed and when it is published 
or read. The guideline is not continually updated and may not 
reflect the most recent evidence. The guideline addresses only 
the topics specifically identified therein and is not applicable 
to other interventions, diseases, or stages of diseases. This 
guideline does not mandate any particular course of medical 
care. Further, the guideline is not intended to substitute the 
independent professional judgment of the treating provider, 
as the guideline does not necessarily account for individual 
variation among patients. Even if evidence on a topic suggests a 
specific diagnostic and/or treatment action, users and especially 
health professionals may need to decide against the suggested or 
recommended action in view of circumstances related to patient 
values, preferences, comorbidities and disease characteristics; 
available human, monetary and material resources; and 
healthcare infrastructures. EAES provides this guideline on 
an “as is” basis, and makes no warranty, express or implied, 
regarding the guideline.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0046 4-020-07555 -y) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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Conclusion This document summarizes the latest evidence on bariatric surgery through state-of-the art guideline develop-
ment, aiming to facilitate evidence-based clinical decisions.
Keywords Bariatric surgery · Obesity · Guidelines · EAES · GRADE · AGREE II
Preamble
It has been 14 years since EAES has launched the 2004 
guidelines on obesity surgery. A lot has changed in the field 
since then. “Historical” techniques developed by the pio-
neers of bariatric surgery were virtually abandoned (e.g. ver-
tical gastroplasty). Plenty of innovations were added to the 
armamentarium of healthcare professionals for the operative 
and perioperative management of bariatric patients. Sleeve 
gastrectomy, although considered experimental in 2004, 
has become the most common bariatric procedure. Most 
recent techniques, such as gastric plication, one-anastomosis 
bypass and endoluminal procedures are gaining increasing 
attention. Reiterative (redo) surgery has gained the interest 
of several bariatric surgeons, although clear indications and 
even a common definition are lacking.
Importantly, laparoscopic surgery is now considered the 
gold standard approach for bariatric surgery. Under consid-
eration of the above, these guidelines focus exclusively on 
minimally invasive bariatric surgery and common surgical 
techniques. Techniques which are now considered obsolete, 
although properly addressed in the previous guidelines, are 
not included in this update. Furthermore, the following top-
ics are not addressed herein: modified laparoscopy (natural 
orifice transluminal, single-incision and robotic surgery), 
intragastric balloons, the impact of emerging technologies 
(3-D, fluorescence, hybrid) and pure metabolic surgery 
(without the obesity parameter).
Former standards of clinical guidance development, 
although of quality at the time, were replaced by the most 
evidence-based development and reporting standards sum-
marized by the GRADE methodology and AGREE II 
guidelines. The support of the EAES Guideline Subcom-
mittee is hereto commended.
The complex treatment of obesity and its comorbidi-
ties requires multidisciplinary integration. To this end, we 
invited the participation of European organizations involved 
in the research and management of obesity. The European 
Chapter of the International Federation for the Surgery of 
Obesity and Metabolic Disorders (IFSO-EC), the European 
Association for the Study of Obesity (EASO) and the Euro-
pean Society for the Peri-operative Care of the Obese Patient 
(ESPCOP) joined their forces with EAES to produce high 
quality work. Their representatives carried a wide variety of 
competencies (psychologists, obesity physicians, nutritional 
experts, anesthetists, laparoscopic surgeons) and comprised 
a concerted multidisciplinary panel. This is the first guide-
line with active involvement of a patient representative from 
the EASO patient task force.
Upon completion of the guideline manuscript, 2 promi-
nent experts in bariatric surgery from outside Europe were 
invited to appraise the work against AGREE II criteria and 
provided their assessment with the AGREE II tool.
Finally, we are obligated to deeply thank all those who 
have contributed to this project, which we hope will con-
tribute to the quality of healthcare in bariatric patients in 
Europe.
Nicola Di Lorenzo & Gianfranco Silecchia
Content Coordinators
Obesity is a multifactorial disease caused by a combina-
tion of genetic, environment and metabolic factors [1]. From 
a public health perspective, obesity is a major risk factor 
for a range of chronic diseases including type 2 diabetes, 
cardiovascular diseases and cancer [2].
History
The first guidelines endorsing surgery for the management of 
morbid obesity were published in 1991 by the US National 
Institutes of Health (NIH) [3]. After this first regulatory 
act, several international guidelines and consensus projects 
recommended bariatric surgery as an effective treatment of 
weight loss and obesity-related comorbidities.
After the introduction of laparoscopic bariatric surgery, 
EAES and the Society of American Gastrointestinal and 
Endoscopic Surgeons (SAGES) launched clinical prac-
tice guidelines in 2004 and 2008, respectively [4, 5]. The 
“Interdisciplinary European Guidelines” on surgery for 
severe obesity were published in 2008, and updated in 2014 
through an expert-based consensus process [6, 7].
Rationale and objective
The growing burden of obesity in both industrialized and 
non-industrialized countries [2], the recognition of obesity 
as a disease in 2013 by the American Medical Association 
and other regulatory bodies [8], the ever-increasing research 
evidence in the field and the lack of recent clinical guidance, 
mandate an urgent need to incorporate latest evidence into 
clinical practice guidelines. EAES recognized this need and 
decided to sponsor the present update, which ultimately aims 
to inform healthcare in bariatric patients.
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Where do these guidelines apply?
These guidelines apply to adult (age > 18) patients with 
body mass index (BMI) > 35 kg/m2 who are considered fit 
for surgery and with no contraindications to laparoscopic 
surgery, unless otherwise indicated. They do not apply to 
the pediatric population. Healthcare systems, infrastructures, 
human and financial resources across European countries 
were considered upon developing these guidelines. There-
fore, they are primarily intended to be applicable in Euro-
pean countries, although some recommendations might be 
applicable to other regions with modifications.
Who are the target users?
The present guidelines may be used by healthcare profes-
sionals, including bariatric surgeons, laparoscopic surgeons, 
obesity physicians, anesthetists, general practitioners, nutri-
tional experts, psychologists, obstetrics and gynecologists, 
anesthetic and intensive care unit staff; and may be used as 
a reference to policymakers, such as European and national 
authorities, healthcare administrators and health insurance 
providers, under consideration that the external validity may 
vary across countries, regions and healthcare institutions.
How long are these guidelines valid for?
In view of current and ongoing research in the field, these 
guidelines are valid from publication up to December 2024. 
Target users are instructed to monitor upcoming research 
(research published from November 2018 onwards) which 
might provide evidence further supporting or even negating 
recommendations provided herein. For further information, 
see Disclaimer.
Update and monitoring
The content coordinators will monitor the literature and will 
recommend an update of these guidelines in 2023, unless 
developments in the field and emerging evidence will sug-
gest an earlier or later update.
A web-based survey of EAES, IFSO-EC, EASO and 
ESPCOP is planned to be launched in October 2021 to 
assess guidelines use among healthcare professionals and 
collect feedback on implementation barriers.
Material and methods
Please see Supplementary file 1 for a detailed report of the 
methodology.
This guideline was developed in accordance with the 
GRADE methodology and complied with AGREE II 
guideline development and reporting standards [9, 10]. Insti-
tutional review board approval and written consent were not 
required. The systematic review and synthesis of evidence 
conformed to PRISMA and MOOSE reporting standards, as 
appropriate [11, 12].
Guideline development group
The steering group consisted of bariatric surgeons, members 
of the EAES Consensus & Guideline Subcommittee and a 
GRADE methodologist [13]. The panel was comprised of 
bariatric surgeons, obesity physicians, nutritional experts, 
psychologists, anesthetists and a patient representative 
(“Appendix”).
Topics
PICO (Patient, Intervention, Comparator, Outcomes) ques-
tions were organized into seven domains:
1. Indication for surgery.
2. Preoperative work-up.
3. Perioperative management.
4. Bariatric procedures.
5. Revisional surgery.
6. Postoperative care.
7. Investigational procedures.
A full list of PICO questions can be found in Supplemen-
tary file 2.
Systematic review
The literature search was confined from 2005 onwards to 
capture the most pertinent evidence under consideration of 
advances in surgical techniques, operative equipment and 
accumulated surgical experience, and to serve as an update 
of previous EAES guidelines [4]. The last search was run in 
November 2018. The search summary and the search syntaxes 
are provided in Supplementary files 3 and 4. PRISMA flow 
charts of record selection are provided in Supplementary file 5.
We considered meta-analyses of randomized controlled 
trials (RCTs), meta-analyses of cohort studies, or individual 
RCTs and cohort studies addressing similar PICO frameworks 
to those of the predefined questions. Overarching inclusion cri-
teria across PICO questions were adult patients (age > 18 years) 
with body mass index > 35 kg/m2 (unless otherwise indicated) 
and laparoscopic surgery (in relevant topic domains). Studies 
addressing bariatric procedures were considered for recom-
mendation only if they provided data on weight loss with a 
follow-up of at least 5 years. Animal studies, studies on pedi-
atric patients and on robotic or open surgery were discarded. 
A total of 65 systematic reviews were performed.
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Evidence synthesis
In the presence of a recent meta-analysis in the context of 
interest, summary effect measures and interval estimates, 
and risk of bias parameters were considered for assessment 
of the quality of evidence as per GRADE methodology [9, 
14]. If no recent meta-analysis was available, we searched 
for relevant RCTs and/or cohort studies and we extracted 
summary data [15, 16]. We performed pairwise meta-anal-
yses using a fixed or random-effects model, as appropriate. 
For adjustable gastric banding, we performed proportion 
meta-analysis to summarize the incidence of related com-
plications and reoperations. Forest plots and funnel plots 
(where available) can be provided by the authors upon rea-
sonable request.
We generated evidence tables, summarizing judgments 
on study design, risk of bias, inconsistency, indirectness, 
imprecision and the overall quality of evidence on each out-
come of interest [17, 18].
Evidence‑to‑decision framework
Predefined parameters were taken into account to formu-
late recommendations. More specifically, importance of the 
problem, desirable/undesirable effects and their balance, the 
certainty (quality) of evidence, patient values and prefer-
ences, acceptability to key stakeholders, cost of implemen-
tation and feasibility of incorporating the intervention into 
practice were considered through research evidence, where 
available, or through panel consensus [19]. Under considera-
tion of these parameters, the panel provided for each PICO 
question:
• A strong recommendation for the intervention or the 
comparator,
• A conditional recommendation for the intervention or the 
comparator, or
• No recommendation (conditional recommendation for 
either the intervention or the comparator) [19].
If no recommendation could be formulated on a PICO 
question, the panel had the option to draft a position state-
ment. Position statements reflect the opinion of the panel, 
are not necessarily based upon research evidence and should 
not be considered formal, evidence-based recommendations.
We used the GRADEpro GDT software (enterprise ver-
sion) for generation of evidence tables, development of rec-
ommendations and Delphi process. [20].
Delphi process
The recommendation drafts, along with background evi-
dence and judgements on the above parameters, were 
subjected to a web-based Delphi process involving all panel 
members, using PanelVoice 2.0 add-on to GRADEpro. 
Three Delphi rounds took place overall.
Survey
Members of participating societies were surveyed to inves-
tigate the applicability of recommendations to their prac-
tice. Further, attendees of the  27th International Congress of 
EAES were invited to participate in an on-site survey using a 
smartphone application in a dedicated session. Results of the 
online survey are provided in Supplementary file 6.
Appraisal
The full guideline in its final version was reviewed by 2 
prominent obesity surgeons and was appraised using the 
AGREE II tool. Their appraisal can be found in Supple-
mentary file 7.
Results
A summary list of recommendations can be found in Table 1. 
The decision trees depicted in Figs. 1, 2, 3, 4, and 5 sche-
matically summarize the recommendations.
Topic 1: indication for bariatric surgery
Bariatric surgery versus medical management 
for morbid obesity
Laparoscopic bariatric surgery should be considered for patients 
with BMI ≥ 40 kg/m2 and for patients with BMI ≥ 35–40 kg/m2 
with associated comorbidities that are expected to improve with 
weight loss
Strong recommendation
Laparoscopic bariatric/metabolic surgery should be considered 
for patients with ≥ BMI 30–35 kg/m2 and type 2 diabetes and/or 
arterial hypertension with poor control despite optimal medical 
therapy
Strong recommendation
Justification
Fifteen RCTs were identified comparing weight loss after bari-
atric surgery or medical therapy (5 reporting on RYGB, 3 on 
LAGB and the rest on mixed patient populations undergoing 
sleeve gastrectomy, BPD/DS, sleeve gastrectomy and/or band-
ing) [21–35]. Random-effects meta-analysis was performed due 
to conceptual heterogeneity in operative interventions and non-
operative management. A RCT performed in a mixed population 
Surgical Endoscopy 
1 3
(RYGB, sleeve gastrectomy, banding) reported a weighted mean 
difference (WMD) of 53% (95% confidence interval, CI, 42% 
to 63%) excess weight loss (EWL) compared to non-operative 
management [34]. Similarly, meta-analysis of 4 RCTs suggested 
a WMD of post-intervention weight of − 19 kg (95% CI − 27 
to − 12) in favor of bariatric surgery, associated with moderate 
and low certainty of the evidence, respectively. These data lend 
support to the results of the Swedish Obese Subjects study, a 
large cohort study comparing bariatric surgery versus medical 
management in the very long term [36].
There were small or non-important differences for sev-
eral metabolic surrogates. However, there was very strong 
association between bariatric surgery and type II diabetes 
(T2DM) resolution (odds ratio, OR, 29, 95% CI 13 to 67) 
and moderate reduction of systolic blood pressure. These 
effects were observed even in RCTs enrolling patients with 
BMI 30–35 kg/m2.
Non-operative management was associated with lower 
odds of complications (OR 2.44, 95% CI 1.47 to 4.06), 
although authors typically did not distinguish between minor 
and major complications, and certainty of the evidence was 
very low (Supplementary Table S1). There was insufficient 
evidence to support cost-effectiveness of operative manage-
ment, however, the panel anticipated significant savings in 
terms of pharmacological management of comorbidities and 
other medical and social interventions.
Topic 2: preoperative work‑up
Preoperative H. pylori eradication versus standard 
care in patients undergoing bariatric surgery
No recommendation can be made for either routine H. pylori 
eradication or no eradication prior to bariatric surgery on the basis 
of available evidence. Conditional recommendation for either the 
intervention or the comparator
Justification
There was no direct comparative observational evidence on 
the effect of H. pylori eradication in bariatric patients. One 
meta-analysis of 4 observational studies comparing H. pylori-
positive- versus H. pylori-negative status was identified [37]. 
The odds for marginal ulcer (OR 0.51, 95% CI 0.03 to 8.35) 
and postoperative complications after bariatric surgery (OR 
2.86, 95% CI 0.26 to 31.27) was similar for H. pylori-positive- 
versus H. pylori-negative patients, albeit interval estimates 
were extremely wide and uncertainty of the evidence high. 
Similarly, there was no firm evidence on postoperative bleed-
ing (OR 0.90, 95% CI 0.23 to 3.52) or leakage (OR 1.62, 
95% CI 0.17 to 15.62). Another meta-analysis, yielding 
seven studies with 255,435 patients, found similar results 
[38]. Multivariable analysis of a registry cohort found H. 
pylori status to be the most important independent predictor 
of marginal ulceration in patients undergoing RYGB, but it 
had little impact on the outcome of other bariatric operations 
[39]. Indirectness of the evidence and imprecision of effect 
estimates were major parameters to judge the quality of evi-
dence, which was very low across outcomes (Supplementary 
Table S2). This is reflected in a conditional recommendation 
for either routine eradication or alternative practice.
Preoperative diet consultation versus standard care 
in patients undergoing bariatric surgery
Preoperative dietitian consultation should be considered for patients 
undergoing bariatric surgery
Strong recommendation
Justification
A meta-analysis reporting 3 RCTs was found on this topic 
[40]. Analyses were re-performed due to error in the primary 
meta-analysis (calculation of WMD instead of standardized 
MD, SMD). The overall quality of evidence was very low 
for weight loss and low for postoperative complications due 
to risk of bias across RCTs, inconsistency (conceptual and 
statistical heterogeneity due to variety of preoperative inter-
ventions for weight loss, and heterogeneity in the duration of 
follow-up) and indirectness (follow-up duration for weight 
loss insufficient for generalizability of findings). Postopera-
tive weight loss was more pronounced in the preoperative 
diet consultation group (SMD 0.4, 95% CI 0.03 to 0.78 
higher). No difference in the odds of postoperative com-
plications was found (risk ratio, RR, 0.80, 95% CI 0.22 to 
2.86), although interval estimates were wide. Confidence in 
the evidence was generally low (Supplementary Table S3), 
however the panel favored a strong recommendation after 
consulting with the patient representative who expressed 
a strong preference for a holistic approach of the bariatric 
patient with continuous preoperative and postoperative con-
sultation. The panel considered this practice feasible, requir-
ing moderate human and financial resources, and being 
acceptable to stakeholders. There was no evidence of any 
risk for the intervention according to the panel’s judgement.
Preoperative endoscopy versus no endoscopy 
in patients undergoing bariatric surgery?
Esophagogastroscopy can be considered as routine diagnostic test 
prior to bariatric surgery
Conditional recommendation
 Surgical Endoscopy
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Table 1  Summary of recommendations
Indication for bariatric 
surgery
Laparoscopic bariatric surgery should be considered for patients with 
BMI ≥ 40 kg/m2 and for patients with BMI ≥ 35–40 kg/m2 with 
associated comorbidities that are expected to improve with weight 
loss
Strong
Laparoscopic bariatric/metabolic surgery should be considered for 
patients with ≥ BMI 30–35 kg/m2 and type 2 diabetes and/or arte-
rial hypertension with poor control despite optimal medical therapy
Strong
Preoperative work-up No recommendation can be made for either routine H. pylori eradica-
tion or no eradication prior to bariatric surgery on the basis of 
available evidence
Conditional for either intervention or comparator
Preoperative dietitian consultation should be considered for patients 
undergoing bariatric surgery
Strong
Esophagogastroscopy can be considered as a routine diagnostic test 
prior to bariatric surgery
Conditional
Psychological evaluation can be considered before bariatric surgery
A previous diagnosis of binge eating or depression may not be con-
sidered as an absolute contraindication to surgery
Conditional
Perioperative manage-
ment
Screening for obstructive sleep apnea using the STOP-BANG criteria 
can be considered prior to bariatric surgery
Conditional
Perioperative CPAP should be considered in patients with severe 
obstructive sleep apnea syndrome who are undergoing bariatric 
surgery
Strong
No recommendation can be made on the dose and duration of phar-
macological thromboprophylaxis in patients after bariatric surgery
Conditional for either intervention or comparator
Inferior vena cava filter is not recommended for thromboprophylaxis 
in patients undergoing bariatric surgery
Strong
No recommendation for either an ERAS protocol or standard care 
can be made on the basis of available evidence
Conditional for either intervention or comparator
Perioperative multimodal analgesia with minimal opioid usage may 
be considered in patients undergoing bariatric surgery
Conditional
Non-bypass proce-
dures
Adjustable gastric banding surgeries are associated with a high rate 
of reoperations for complications or conversion to another bariatric 
procedure for insufficient weight loss in the long term
Position statement
Sleeve gastrectomy may be preferred over adjustable gastric banding 
for weight loss and control/resolution of metabolic comorbidities
Conditional
Sleeve gastrectomy may offer improved short-term weight loss and 
resolution of type 2 diabetes compared to gastric plication. No sig-
nificant differences are observed at mid-term. Long-term compara-
tive data on weight loss and metabolic effects are, however, lacking
Position statement
There is insufficient evidence to recommend routine stapler line 
 reinforcementa to reduce the leak rate
Position statement
Staple line  reinforcementa in sleeve gastrectomy should be consid-
ered to reduce the risk of perioperative  complicationsb
Strong
A bougie size < 36F compared to a bougie sized ≥ 36F may be rec-
ommended for calibration in sleeve gastrectomy as it is associated 
with greater weight loss in the mid-term
Conditional
More extensive antral resection (2–3 cm from the pylorus ver-
sus > 5 cm antral preservation) potentially offers greater weight loss 
in the short term without a significant increase in post-operative 
complications. Long term data are, however, lacking
Position statement
Surgical Endoscopy 
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Table 1  (continued)
Bypass procedures RYGB should be preferred over adjustable gastric banding Strong
RYGB results in greater weight loss and control/remission of insulin 
resistance and type 2 diabetes compared to gastric plication
Position statement
RYGB offers similar mid-term weight loss and control/remission of 
metabolic comorbidities compared to sleeve gastrectomy. Long-
term comparative data are, however, lacking
Position statement
RYGB can be preferred over sleeve gastrectomy in patients with 
severe gastroesophageal reflux disease and/or severe esophagitis
Conditional
No recommendation for either BPD/DS or sleeve gastrectomy can be 
made on the basis of available comparative evidence
Conditional for either intervention or comparator
With regard to mid-term weight loss there is no difference between 
BPD/DS and RYGB. BPD/DS is superior to RYGB for control/
remission of type 2 diabetes. Long-term comparative data are, how-
ever, lacking
Position statement
One anastomosis 
procedures
OAGB may offer greater short-term weight loss compared to RYGB, 
gastric plication, adjustable gastric banding and sleeve gastrectomy. 
Long-term comparative data are, however, lacking. The effect on 
nutritional deficiencies remains controversial
Position statement
No recommendation on SADI-S compared with OAGB, BPD/DS, 
RYGB or sleeve gastrectomy can be made on the basis of available 
evidence
Conditional for either intervention or comparator
Revisional surgery No evidence-based criteria for indication to revisional bariatric/meta-
bolic surgery are available to date
The panel advises that the clinical decision to proceed to revisional 
bariatric/metabolic surgery be based on a complete multidiscipli-
nary assessment of the patient, as recommended for the primary 
procedure
Position statement
Postoperative care Scheduled multidisciplinary post-operative follow-up should be pro-
vided to every patient undergoing bariatric/metabolic surgery
Strong
Treatment with ursodeoxycholic acid could be considered during the 
weight loss phase to prevent gallstones formation
Conditional
Micro and/or macronutrients supplementation is recommended after 
bariatric surgery according to the type of the procedure and to the 
deficiencies documented during the follow-up
Strong
PPI therapy should be given to patients undergoing bypass proce-
dures for the prevention of marginal ulcers
Strong
Postoperative nutritional and behavioral advice should be provided to 
patients undergoing bariatric surgery
Strong
Pregnancy following bariatric surgery should be delayed during the 
weight loss phase
Strong
Investigational proce-
dures
For duodenal-jejunal bypass sleeves, aspiration devices, gastric 
electrical stimulation, vagal blockade and duodenal mucosal 
resurfacing, the quality of evidence was too low to provide any 
recommendations
Position statement
Endoluminal suturing procedures may have a role in the treatment of 
patients with obesity with BMI < 40 kg/m2
Position statement
Position statements do not constitute recommendations. BMI body mass index, CPAP continuous positive airway pressure, ERAS Enhanced 
recovery after surgery, BPD/DS biliopancreatic diversion with duodenal switch, OAGB one anastomosis gastric bypass, SADIS single-anastomo-
sis duodeno-ileal switch, PPI proton-pump inhibitor
a Buttress, glues, suturing, clips
b Overall mortality, bleeding
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Justification
Two systematic reviews were available on this topic [7, 8, 
41, 42] Proportion meta-analyses encompassing 23 obser-
vational studies and 6845 patients suggested a summary 
change in surgical management after esophagogastroscopy 
in 7.8% (95% CI 6.1 to 9.5%). Changes of surgical man-
agement included: hiatal hernia repairs, delays in surgery 
due to gastritis or peptic ulcer disease, major changes in the 
planned procedure and additional endoscopic dissection for 
suspicious lesions. Regarding a change in medical manage-
ment, proportion meta-analysis of 20 observational studies 
reporting on 5140 patients found a management change in 
27.5% (95% CI 20.2 to 34.8%) after esophagogastroscopy. 
Changes of medical management included primarily H. 
pylori eradication and initiation of proton-pump inhibitors 
or histamine blockers for gastritis or reflux [41]. The second 
meta-analysis demonstrated similar findings [42].
In view of the very low certainty owing primarily to risk 
of bias, inconsistency, publication bias, and questionable 
value in certain circumstances, hence indirectness (Supple-
mentary Table S4), the panel provided a conditional recom-
mendation for routine esophagogastroscopy, recognizing 
that selective endoscopy in patients with upper abdominal 
symptoms might be more appropriate.
Assessment of preoperative psychological 
conditions versus no assessment in patients 
undergoing bariatric surgery
Psychological evaluation can be considered before bariatric surgery
A previous diagnosis of binge eating or depression may not be 
considered as an absolute contraindication to surgery
Conditional recommendation
Justification
In a meta-analysis of 26 observational studies, the preva-
lence of mental health disorders was higher among bariatric 
surgery candidates compared to the general population [43]. 
Furthermore, preoperative depression did not seem to be 
associated with postoperative weight loss, whereas there was 
conflicting evidence on binge eating. Due to the inconsist-
ency of evidence, the variable availability of resources, and 
the uncertainty of the acceptability of the intervention to 
stakeholders, the panel provided a conditional recommen-
dation for psychological evaluation before bariatric surgery. 
However, the treating physician should be alert to identify 
discrete signs of psychological disorders and refer those 
patients for further evaluation.
Similarly, due to the uncertainty of evidence and in view 
of the large beneficial effects of bariatric surgery on post-
operative depression (Supplementary Table S5), the panel 
provided a conditional recommendation for bariatric surgery 
in the presence of a previous diagnosis of binge eating or 
Fig. 1  Evidence-based decision 
tree on the decision for bariatric 
surgery or conservative man-
agement. BMI body mass index. 
BMI values are kg/m2. Thick 
arrows and frames, and bold 
fonts indicate strong recom-
mendation
Bariatric surgery 
candidate
BMI ≥40BMI <40 and ≥35
Bariatric/metabolic surgery
no yes
BMI <35 and ≥30
yes no
conservave management
refractory diabetes or hypertension? comorbidies?
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depression. It should be recognized, however, that different 
interventions may have various effects on patients with dif-
ferent psychological backgrounds. Current data do not allow 
subgroup analyses to account for the above. Previous evi-
dence suggests that most mental disorders (mood, anxiety, 
bipolar disorder, eating disorders etc.) might be considered 
as a contraindication for bariatric surgery if the conditions 
are severe and undertreated [44].
Topic 3: perioperative management
Screening versus no screening for obstructive sleep 
apnea in patients prior to bariatric surgery
Screening for obstructive sleep apnea using the STOP-BANG crite-
ria can be considered prior to bariatric surgery
Conditional recommendation
Justification
No observational evidence directly addressing the question 
was found. Meta-analysis of observational studies suggested 
that patients with obstructive sleep apnea or related disor-
ders were more likely to sustain atrial fibrillation (OR 1.51, 
95% CI 1.36 to 1.69) or hypoxemia (WMD − 3.8%, 95% 
CI − 5.4% to − 2.2%) [45–59]. The latter outcome might 
not be clinically important, whereas the summary certainty 
in the evidence was very low due to risk of bias (non-con-
trolled confounders in cohort studies), imprecision, statisti-
cal and conceptual heterogeneity (differences in definition 
of sleep apnea and method of diagnosis) (Supplementary 
Table 6). Nevertheless, screening using the STOP-BANG 
criteria seemed to be predictive of postoperative complica-
tions in several observational studies [3, 4, 8, 9, 47, 48, 52, 
53]. There was no evidence to support cost-effectiveness 
of diagnosis using STOP-BANG against polysomnography, 
however, the panel anticipated cost savings by identifying 
and offering intensive care to patients at risk. The panel 
Preoperave work-up
no
Bariatric/metabolic surgery
yes
yes no
diecian available?
diecian consultaon
endoscopy available?
roune gastroscopy no roune gastroscopy
H. pylori?
yes no
eradicaon no eradicaon
psychological evaluaon* no psychological evaluaon
Fig. 2  Evidence-based decision tree for preoperative work-up. 
*Psychological evaluation should be performed when psychologi-
cal disorders are suspected. Binge eating and depression might not 
be a contraindication for bariatric/metabolic surgery. Thick arrows 
and frames, and bold fonts indicate strong recommendation. Dotted 
arrows and frames indicate conditional recommendation for the inter-
vention. Dashed arrows and frames indicate conditional recommenda-
tion against the intervention
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provided a conditional recommendation for using the criteria 
for sleep apnea screening in candidates for bariatric surgery. 
There was agreement that, in case of clinical suspicion of 
sleep apnea, formal screening be performed.
Perioperative continuous positive airway pressure 
(CPAP) versus no CPAP in patients with severe sleep 
apnea syndrome
Perioperative CPAP should be considered in patients with severe 
obstructive sleep apnea syndrome who are undergoing bariatric 
surgery
Strong recommendation
Meta-analysis of observational studies suggested higher 
odds of postoperative pneumonia (OR 0.24, 95% CI 0.07 
to 0.82), a trend towards lower odds of reintubation (OR 
0.28, 95% CI 0.07 to 1.04), and shorter hospital stay (WMD 
− 1.6 days, 95% CI − 1.83 to − 1.28) albeit relevant evi-
dence was of low certainty due to imprecision and the obser-
vational study design (Supplementary Table S7) [51, 52, 60, 
61]. The panel provided a strong recommendation in spite 
of the low certainty of the evidence, due to the severity of 
these complications in the bariatric patient population and 
the low likelihood of harm associated with the intervention.
Fig. 3  Evidence-based decision 
tree for anesthetic and perio-
perative management. CPAP 
continuous positive airway pres-
sure, IVCF inferior vena cava 
filter, ERAS enhanced recovery 
after surgery. *with minimal use 
of opioids. Thick arrows and 
frames, and bold fonts indicate 
strong recommendation. Dotted 
arrows and frames indicate 
conditional recommendation for 
the intervention. Dashed arrows 
and frames indicate conditional 
recommendation against the 
intervention
Anesthec/perioperave 
management
polysomnographySTOP-BANG criteria
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High‑dose versus standard‑dose pharmacological 
antithrombotic prophylaxis after surgery
No recommendation can be made on the dose and duration of phar-
macological thromboprophylaxis in patients after bariatric surgery
Conditional recommendation for either the intervention or the 
comparator
Justification
Two RCTs were identified reporting on high versus standard 
dose low-molecular weight heparin after bariatric surgery 
[62, 63], whereas there was no evidence on the duration of 
prophylaxis. Meta-analysis suggested no significant differ-
ence with regard to deep venous thrombosis or bleeding, 
however, relevant evidence was moderate or low, due to sub-
stantial imprecision (Supplementary Table S8). The panel 
provided, therefore, conditional recommendation for either 
high dose or standard dose prophylaxis.
Inferior vena cava filter versus standard care 
for prevention of thromboembolic events 
after bariatric surgery
Inferior vena cava filter is not recommended for thromboprophy-
laxis in patients undergoing bariatric surgery
Strong recommendation
Meta-analysis of six observational studies suggested higher 
risk of deep venous thrombosis (OR 2.81, 95% CI 1.33 to 
5.97), similar risk of pulmonary embolism (RR 1.02, 95% 
CI 0.31 to 3.37) and a trend towards higher risk of mortal-
ity with inferior vena cava filters (RR 3.27, 95% CI 0.78 to 
13.64), albeit with wide interval estimates (Supplementary 
Table S9) [64]. Due to the importance of these outcomes 
and despite the low certainty of the evidence overall, this 
difference in effect estimates prompted the panel to provide 
a strong recommendation against the use of filters outside a 
research protocol.
Fig. 4  Evidence-based deci-
sion tree for the selection of 
operative approach. BPD/
DS biliopancreatic diversion 
with duodenal switch, AGB 
adjustable gastric banding, 
GERD gastroesophageal reflux 
disease, RYGB Roux-en-Y gas-
tric bypass. Thick arrows and 
frames, and bold fonts indicate 
strong recommendation. Dotted 
arrows and frames indicate 
conditional recommendation for 
the intervention. Dashed arrows 
and frames indicate conditional 
recommendation against the 
intervention
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Enhanced recovery after surgery (ERAS) protocol 
versus standard care for bariatric surgery
No recommendation for either an ERAS protocol or standard care 
can be made on the basis of available evidence
Conditional recommendation for either the intervention or the 
comparator
Justification
Two meta-analyses of 11 observational and randomized 
studies addressed the comparative effect of ERAS versus 
standard care in bariatric surgery [1, 2, 65, 66] No differ-
ences were found in major (OR 0.94, 95% CI 0.58 to 1.51) 
and minor postoperative complications (OR 0.88, 95% CI 
0.55 to 1.41), and mortality (RR 0.4, 95% CI 0.1 to 2.2). 
Hospital stay was shorter for ERAS with a mean difference 
of 2.4 days (95% CI − 3.9 to − 0.9). The certainty of the 
evidence was very low primarily due to the observational 
study design, within-study risk of bias and wide interval 
estimates. Statistical inconsistency was also evident, prob-
ably reflecting conceptual heterogeneity of different ERAS 
protocols (Supplementary Table S10). In view of these find-
ings, the panel did not favor either practice and invites fur-
ther research.
Multimodal analgesia with minimal use of opioids 
versus standard analgesia in bariatric surgery
Perioperative multimodal analgesia with minimal opioid usage may 
be considered in patients undergoing bariatric surgery
Conditional recommendation
Justification
Four observational studies and seven RCTs were identified 
reporting on multimodal postoperative analgesia in lapa-
roscopic bariatric surgery [3–13, 67–76] Random-effects 
meta-analyses to account for conceptual heterogeneity in 
analgesia protocols were performed. Most outcomes were 
addressed by few studies, hence effect estimates were not 
precise. Multimodal analgesia was associated with lower 
visual analog scale (VAS) scores and shorter stay in a post-
anesthesia care unit (PACU). Of note, the odds for postop-
erative nausea and vomiting were lower with multimodal 
analgesia (OR 0.40, 95% CI 0.25 to 0.64). There was a mar-
ginal benefit of multimodal analgesia with regard to post-
operative pneumonia (RD − 0.02, 95% CI − 0.05 to 0.00). 
There was high certainty of evidence for the latter findings 
and very low certainty for other critical outcomes (Supple-
mentary Table S11), which prompted the panel to provide a 
conventional recommendation for multimodal analgesia with 
minimal use of opioids. This practice may be particularly 
considered in patients at increased risk for opioid sensitivity 
and obstructive sleep apnea.
Topic 4: operative procedures
Non‑bypass procedures
Adjustable gastric banding
Position Statement
Adjustable gastric banding surgeries are associated with a high rate 
of reoperations for complications or conversion to another bariat-
ric procedure for insufficient weight loss in the long term
Follow-up
yes
muldisciplinary team available?
yes no
PPI therapy
behavioral and 
nutrional advice
no
follow-up by 
muldisciplinary team
bypass procedure?
pregnancy desired?
delay pregnancy unl 
weight stabilized
Fig. 5  Evidence-based decision tree for postoperative follow-up. PPI 
proton-pump inhibitor. Thick arrows and frames, and bold fonts indi-
cate strong recommendation
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Justification
Proportion meta-analysis of randomized and observational 
studies found a pooled incidence of 20% (95% CI 13% to 
26%, df = 10, I2 = 89%) for complications requiring surgi-
cal intervention, 2% (95% CI 1% to 3%, df = 7, I2 = 0%) for 
band erosion, 7% (95% CI 4% to 10%, df = 9, I2 = 72%) for 
band removal, 4% (95% CI 3% to 5%, df = 6, I2 = 0) for port 
revision, and 19% (95% CI 12 to 26%, df = 8, I2 = 85%) for 
overall complications [77–89].
Four studies with a follow-up of at least 5 years were 
identified. Port-related and band-related complications were 
documented for 18%, 23%, 27% and 43% of patients [78, 80, 
85, 89]. Re-interventions for insufficient weight loss were 
reported by 3 studies at follow-up > 5 years, and documented 
for 6%, 12% and 18% of patients [78, 80, 85]. Port revisions 
occurred most commonly in the first year following surgery; 
reversals and conversions were more common during years 
2 through 5. In view of this cumulative evidence, the panel 
provided a position statement on adjustable gastric banding.
Sleeve gastrectomy versus adjustable gastric 
banding
Sleeve gastrectomy may be preferred over adjustable gastric band-
ing for weight loss and control/resolution of metabolic comorbidi-
ties
Conditional recommendation
Justification
Two network meta-analyses were available reporting on 
weight loss and diabetes remission [90, 91]. Sleeve gastrec-
tomy was associated with a weighted mean difference of 
25% EWL (95% CI 6.4% to 41%) and 57% higher odds of 
diabetes remission (OR 0.43, 95% CI 0.19 to 0.98). The 
network for weight loss was sparse with one direct and mul-
tiple indirect sources of evidence, which is the main reason 
for downgrading the certainty of evidence to low (Supple-
mentary Table S12). Under consideration of the duration of 
follow-up (mean, 3 years, hence indirectness) and the high 
incidence of band-related complications, the panel provided 
a conditional recommendation for sleeve gastrectomy.
Sleeve gastrectomy versus gastric plication
Position statement
Sleeve gastrectomy may offer improved short-term weight loss and 
resolution of type 2 diabetes compared to gastric plication. No sig-
nificant differences are observed at mid-term. Long-term compara-
tive data on weight-loss and metabolic effects are, however, lacking
Justification
Analysis of long-term (≥ 5  years) and very long-term 
(≥ 10 years) evidence suggested an EWL between 42 and 
55% with a mean weight regain between 9 and 31% for 
sleeve gastrectomy [9, 10, 92, 93]. Comparative long-term 
evidence was sparse, therefore, the panel provided a posi-
tion statement under consideration of short- and mid-term 
outcomes. Meta-analysis of summary outcomes suggests a 
WMD of 31% (95% CI 10 to 72%) in favor of sleeve gas-
trectomy, but higher comparative odds for postoperative 
complications (OR 2.86, 95% CI 1.47 to 5.88) for the latter. 
Certainty of the evidence across outcomes was very low, 
primarily due to observational study design, inconsistency 
and imprecision (Supplementary Table S13).
Technical considerations on sleeve gastrectomy: 
Staple line reinforcement
Position statement
There is insufficient evidence to recommend routine stapler line 
reinforcement* to reduce the leak rate
*Buttress, glues, suturing, clips,
Recommendation
Staple line reinforcement* in sleeve gastrectomy should be consid-
ered to reduce the risk of perioperative complications**
Strong recommendation
*Buttress, glues, suturing, clips,
**Overall mortality, bleeding
Justification
A meta-analysis of RCTs and a proportion meta-analysis 
addressed the topic of staple line reinforcement [94, 95]. 
Staple line reinforcement was associated with a 30% lower 
risk for complications overall (RR 0.7, 95% CI 0.5 to 0.9) 
and this finding was associated with high certainty. There 
was a trend towards lower risks of bleeding (RR 0.56, 95% 
CI 0.25 to 1.27) and leak (0.60, 95% CI 0.27 to 1.50) with-
out reaching significance, however, effect estimates were 
imprecise and the certainty of evidence for these outcomes 
downgraded (Supplementary Table S14). Under considera-
tion of the composite parameters, the feasibility, the cost 
and acceptability to stakeholders, the panel unanimously 
supported a strong recommendation. However, it should 
be noted that available evidence regards buttress material, 
glues, suturing and clips and external validity of these find-
ings applies only to these interventions. Furthermore, evi-
dence on the effect of buttressing material on leak was scarce 
and this is reflected in the panel’s position statement.
According to the Fifth International Consensus Sum-
mit on Sleeve Gastrectomy, 43% of surgeons preferred 
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buttressing material for suture line reinforcement, 29% pre-
ferred oversewing and the remaining 28% did not use suture 
line reinforcement [96].
Technical considerations on sleeve gastrectomy: 
Bougie size
A bougie size < 36F compared to a bougie sized ≥ 36F may be rec-
ommended for calibration in sleeve gastrectomy as it is associated 
with greater weight loss in the mid-term
Conditional recommendation
Justification
A meta-analysis of observational studies comparing sleeve 
gastrectomy with bougie > 36F or < 36F was identified [97]. 
The use of bougie of smaller caliber was associated with 
more pronounced weight loss (SMD 0.23, 95% CI 0.14 to 
0.33) and this finding was associated with moderate cer-
tainty. There was no difference in the odds for leak (OR 0.67, 
95% CI 0.67 to 1.24), overall complications (OR 1.00, 95% 
CI 0.73 to 1.37) or gastroesophageal reflux (OR 0.77, 97% 
CI 0.37 to 1.59), albeit the certainty of the evidence was very 
low (Supplementary Table S15). The panel provided a con-
ditional recommendation for the use of bougie sized < 36F.
The Fifth International Consensus Summit survey found 
that bariatric surgeons tend to use a larger bougie than previ-
ously recorded, the median size being 36F, most probably 
to avoid strictures and leak associated with stricture [96]. 
One of the widest differences between the consensus sum-
mit report of 2011 and 2014 is that more experts believe 
that smaller bougies are associated with stricture and leaks, 
hence the tendency to use bougies of larger diameter (from 
65% in 2011 to 79% in 2014, P = 0.006) [96].
Technical considerations on sleeve gastrectomy: 
antral resection
Position Statement
More extensive antral resection (2–3 cm from the pylorus ver-
sus > 5 cm antral preservation) potentially offers greater weight 
loss in the short term without a significant increase in post-opera-
tive complications. Long term data are, however, lacking
Justification
A meta-analysis of 6 randomized and 2 observational stud-
ies addressed this topic [98]. Weight loss was more pro-
nounced with antral resection (SMD 0.95, 95% CI 0.32 to 
1.58), with no differences in staple line leak (RR 1.87, 95% 
CI 0.46 to 7.61), bleeding (RR 1.27, 95% CI 0.40 to 4.01) or 
gastroesophageal reflux (0.69, 95% CI 0.26 to 1.82). Never-
theless, certainty in the evidence was very low across out-
comes due to the observational study design, risk of bias and 
imprecision (Supplementary Table S16). The panel decided 
that there was insufficient evidence to form a recommenda-
tion and a position statement was provided instead.
In the Fourth International Consensus Summit survey, 
bariatric surgeons reported that they resect the antrum at 
4–5 cm (32%), 3–4 cm (27%), or 5–6 cm (22%) proximal to 
the pylorus [99].
Bypass procedures
Roux‑en‑Y gastric bypass (RYGB) versus adjustable 
gastric banding
RYGB should be preferred over adjustable gastric banding
Strong recommendation
Justification
Two network meta-analyses including outcomes of pairwise 
comparisons addressed weight loss and diabetes remission 
after RYGB and adjustable gastric banding [90, 91]. The 
WMD of EWL was 22% (95% CI 6.5% to 34%) in favor of 
RYGB, which was associated with high certainty evidence. 
There was no difference in diabetes remission (RR 1.96, 
95% CI 0.47 to 8.33), although certainty of the evidence 
was low (Supplementary Table S17). Nevertheless, mixed 
(direct and indirect) effect estimates were in favor of RYGB 
(RR 2.65, 95% CI 1.16 to 6.07) [91]. There was no summary 
evidence of perioperative complications, however, the panel 
unanimously supported a strong recommendation for RYGB 
over adjustable gastric banding, as it was judged that benefits 
outweigh potential risks.
RYGB versus gastric plication
Position Statement
RYGB results in greater weight loss and control/remission of insu-
lin resistance and type 2 diabetes compared to gastric plication
Justification
Aggregate data were available for the outcome diabetes 
remission [91]. A network meta-analysis found RYGB to 
be associated with higher odds for remission compared to 
gastric plication (RR 4.00, 95% CI 1.40 to 11.11), albeit 
certainty was low due to imprecision and risk of bias 
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(Supplementary Table S18). Mixed effect estimates were 
more precise (RR 2.86, 95% CI 1.17 to 6.98), however, still 
wide. The panel considered this evidence to be insufficient 
to form a recommendation and, in view of the scarcity of 
long-term data, provided a position statement instead. The 
statement on weight loss is based on indirect and empirical 
evidence suggesting a durable effect of weight loss com-
pared to gastric plication.
RYGB versus sleeve gastrectomy
Position Statement
RYGB offers similar mid-term weight loss and control/remission of 
metabolic comorbidities compared to sleeve gastrectomy. Long-
term comparative data are, however, lacking
RYGB can be preferred over sleeve gastrectomy in patients with 
severe gastroesophageal reflux disease and/or severe esophagitis
Conditional recommendation
Justification
A meta-analysis of observational studies, two meta-analyses 
of RCTs and two network meta-analyses addressed the com-
parative outcomes of RYGB and sleeve gastrectomy [90, 
91, 100–102]. There was no significant difference in EWL 
(WMD − 4%, 95% CI − 14% to 8%) or diabetes remission 
(RR 0.89, 95% CI 0.73 to 1.06), findings supported by mod-
erate certainty of evidence. There was marginal difference in 
major operative morbidity (OR 2.04, 95% CI 1.00 to 4.16), 
no differences in minor perioperative complications (OR 
1.43, 95% CI 0.60 to 3.23), and long-term minor (OR 0.64, 
95% CI 0.28 to 1.47) or major complications (OR 0.64, 95% 
CI 0.21 to 1.96), although the latter outcomes were associ-
ated with low or very low certainty of evidence. Remission 
of dyslipidemia and hypertension were in favor of sleeve 
gastrectomy, but certainty of the evidence was very low due 
to observational study design, risk of bias, inconsistency and 
indirectness (Supplementary Table S19).
Two RCTs addressed gastroesophageal reflux after RYGB 
and sleeve gastrectomy [103, 104]. Remission of pre-exist-
ing gastroesophageal reflux (absolute difference − 0.36, 95% 
CI − 0.57 to − 0.15) and de novo gastroesophageal reflux 
was more often seen after sleeve gastrectomy (absolute dif-
ference − 0.31%, 95% CI − 0.08% to − 0.54%) (moder-
ate and low certainty of evidence). Under consideration of 
the low certainty of evidence in important outcomes and 
the lack of long-term (> 5 years) data, the panel provided a 
position statement on the comparative effect in the general 
bariatric population and a conditional recommendation for 
patients with reflux disease.
Biliopancreatic diversion with duodenal switch 
(BPD/DS) versus sleeve gastrectomy
No recommendation for either BPD/DS or sleeve gastrectomy can 
be made on the basis of available comparative evidence
Conditional recommendation for either the intervention or the 
comparator
Justification
Evidence on BPD/DS was very scarce, probably due to lim-
ited diffusion of this technique in bariatric surgeons [105]. 
Only 2 cohort studies were identified, which addressed 
morbidity and mortality [106, 107]. Effect estimates was 
summarized with meta-analysis, however, the certainty of 
evidence was very low due to imprecision (Supplementary 
Table S20). As such, the panel did not provide a recommen-
dation for BPD/DS or sleeve gastrectomy.
BPD/DS versus RYGB
Position Statement
With regard to mid-term weight loss there is no difference between 
BPD/DS and RYGB. BPD/DS is superior to RYGB for control/
remission of type 2 diabetes. Long-term comparative data are, 
however, lacking
Justification
Four RCTs were identified and outcomes were meta-ana-
lyzed [27, 108–110]. Despite low risk of bias across trials, 
effect estimates were imprecise and indirectness significant, 
because no long-term data were available. EWL was similar 
(WMD 14%, 95% CI − 12.21 to 42.15, very low certainty), 
whereas long-term morbidity (OR 3.38, 95% CI 1.14 to 
10.05, low certainty) and diabetes remission (OR 8.06, 95% 
CI 1.35 to 48.14) were in favor of RYGB (Supplementary 
Table S21).
A matched cohort study on 73,702 patients from the Bar-
iatric Outcomes Longitudinal Database reported BPD/DS 
to be associated with the greatest adjusted change in BMI 
compared to RYGB and sleeve gastrectomy. The study also 
suggested that BPD/DS was superior in terms of diabetes 
remission [111].
Due to conflicting evidence and generally low certainty 
across outcomes, no recommendation was provided by the 
panel.
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One anastomosis procedures
One anastomosis gastric bypass (OAGB)
Position Statement
OAGB may offer greater short-term weight loss compared to 
RYGB, gastric plication, adjustable gastric banding and sleeve 
gastrectomy. Long-term comparative data are, however, lacking. 
The effect on nutritional deficiencies remains controversial
Justification
OAGB is an emerging bariatric procedure which gains 
increasing interest among bariatric surgeons. According to 
the First IFSO Consensus Statement, the panel unanimously 
supported that OAGB is an acceptable mainstream surgical 
option and 96% considered that it may no longer be regarded 
as new or experimental procedure [112].
As a recently developed procedure, relevant evidence was 
limited. Certainty of the evidence was moderate across most 
outcomes for the comparison OAGB versus RYGB with only 
2 RCTs, which were meta-analyzed, and a network meta-
analysis addressing the comparison [91, 113, 114] .Quality 
of life and resolution of comorbidities was similar. OAGB 
was associated with marginally reduced odds for in-hospital 
morbidity (OR 0.38, 95% CI 0.13 to 1.14) and late compli-
cations (0.76, 95% CI 0.33 to 1.77) at the expense of less 
pronounced EWL (WMD 13%, 95% CI 2% to 29%; very low 
certainty) (Supplementary Table S22).
A meta-analysis of four observational studies compared 
AGB with one anastomosis gastric bypass (OAGB) [115]. 
OAGB was associated with lower postoperative BMI (WMD 
− 7 kg/m2, 95% CI − 9 to − 4) and smaller waist circumfer-
ence (WMD − 14 cm, 95% CI − 27 to − 1), whereas there 
was no difference in diabetes remission (RR 1.48, 95% CI 
0.98 to 2.25) at a mean follow-up of 1 year (Supplementary 
Table S23).
Two meta-analyses addressed the comparison OAGB 
versus sleeve gastrectomy [116, 117]. As they combine ran-
domized and observational data, we meta-analyzed RCTs 
only to increase certainty in the evidence, when possible 
[114, 118]. EWL was more pronounced with sleeve gastrec-
tomy (WMD 20%, 95% CI 20 to 23) and this finding was 
supported with high certainty in the evidence. The analysis 
favored sleeve gastrectomy in terms of diabetes and dyslipi-
demia remission and there was a trend towards lower odds 
for morbidity for OAGB (OR 0.67, 95% CI 0.28 to 1.61) 
(Supplementary Table S24). One RCT compared OAGB ver-
sus gastric plication, which provided very limited evidence 
(Supplementary Table S25) [119].
Under consideration of the lack of long-term data, the 
panel provided a position statement and no recommendation.
Single anastomosis duodeno‑ileal bypass 
withsleeve gastrectomy (SADI‑S)
No recommendation on SADI-S compared with OAGB, BPD/DS, 
RYGB or sleeve gastrectomy can be made on the basis of avail-
able evidence
Conditional recommendation for either the intervention or the 
comparator
Justification
SADI-S represents a simplified modification of the BPD/DS. 
There was limited evidence across comparisons.
One observational study investigated the comparative 
effect of SADI-S and RYGB, providing very low certainty 
evidence (Supplementary Table S26) [120]. Similarly, one 
observational study addressed SADI-S versus BPD/DS (Sup-
plementary Table S27) and one addressed SADI-S versus 
sleeve gastrectomy (Supplementary Table S28) [121, 122].
Topic 5: revisional surgery
Position Statement
No evidence-based criteria for indication to revisional bariatric/
metabolic surgery are available to date
The panel advises that the clinical decision to proceed to revisional 
bariatric/metabolic surgery be based on a complete multidiscipli-
nary assessment of the patient, as recommended for the primary 
procedure
Terminology
The increasing use of bariatric/metabolic surgery was 
accompanied by a parallel increase of the number of patients 
who received an additional bariatric procedure after the 
index one [123]. In 2014, the American Society for Meta-
bolic & Bariatric Surgery performed a systematic review on 
re-operative bariatric surgery and proposed a nomenclature 
for dividing the secondary procedures based on the technical 
aspects (Supplementary Table S29) [124].
Reoperations after bariatric surgery may be primarily per-
formed for two reasons: (a) to solve or fix complications or 
side effects linked to the primary procedures; (b) to improve 
the results in patients with insufficient weight loss, continued 
or poorly controlled comorbid disease, or weight regain. We 
suggest the use of the term revisional bariatric/metabolic 
surgery only for re-operative procedures performed for the 
second group of indications. Revisional surgery can correct 
or convert the primary procedure. The surgical procedures 
targeting the first category of indications are re-interven-
tions indicated by the patient’s medical condition, performed 
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electively or in emergency, and they can include conver-
sions, corrective or reversal procedures.
Severe obesity is a chronic disease that requires lifetime 
treatment. While bariatric/metabolic surgery is usually an 
effective and durable therapy, there will be patients who 
respond well to the initial therapy and others with only 
partial response, as in many other chronic diseases requir-
ing medical or surgical therapy. There will be also a subset 
of patients having recurrent or persistent disease. These 
patients may require escalation of therapy or a new treatment 
modality [124]. We, therefore, suggest that the term “failure” 
or “failed” in respect to metabolic/bariatric procedures be 
abandoned. The term “non-responders” should be adopted 
because it is more consistent with the frame of obesity as 
chronic disease.
Clinical indications for revisional surgery
We define as revisional bariatric/metabolic surgery any 
re-operative bariatric procedure performed to improve the 
results in patients with insufficient weight loss, continued 
comorbid disease, or weight regain. However, an estab-
lished consensus on which levels of insufficient weight loss 
or weight regain should be considered as indicators for the 
need of a revisional procedure is still lacking.
Bonouvrie et al. recently performed a systematic review 
illustrating the lack of standard definitions of non-responders 
after bariatric surgery [125]. This is partly due to hetero-
geneity among studies which precludes evidence synthesis 
for revisional surgery. There is an urgent need to introduce 
standard definitions to be used in future research and clinical 
practice. Current definitions remain arbitrary, due to the lack 
of solid evidence in this field. A set of diagnostic criteria is 
proposed in Supplementary Table S30, taking into consid-
eration current indications for bariatric/metabolic surgery 
and the evidence on the positive effects of a 10% weight 
loss [126].
Work‑up in case of revisional surgery
Current evidence suggests that revisional surgery may confer 
an improvement of obesity and obesity-related comorbidities 
in patients without optimal results after an index procedure. 
Escalation of therapy in patients with poor response should 
be considered rational in the long-term management of a 
chronic disease such as obesity [124]. On the other hand, 
revisional bariatric surgery confers a higher risk of periop-
erative complications than primary bariatric surgery [127]. 
The individual risk/benefit analysis for revisional surgery 
is, therefore, even more complex than for index procedures. 
We suggest that the clinical decision to proceed to revisional 
bariatric surgery be based on a complete multidisciplinary 
assessment, as recommended for the primary procedure, 
including endoscopic and radiological studies, with detailed 
information about the index procedure and proper evaluation 
of nutritional and behavioral status.
Topic 6: postoperative care
Scheduled multidisciplinary post‑operative 
follow‑up versus standard care
Scheduled multidisciplinary post-operative follow-up should be 
provided to every patient undergoing bariatric/metabolic surgery
Strong recommendation
Justification
A meta-analysis of summary data from five RCTs reporting 
patients undergoing a variety of bariatric procedures and 
assessing the impact of scheduled multidisciplinary post-
operative follow-up versus standard care reported more pro-
nounced weight loss in the treatment group [128]. Sched-
uled multidisciplinary post-operative follow-up resulted in 
slightly greater EWL (WMD 1.6%, 95% CI 0.82% to 2.38%) 
compared to the control group (Supplementary Table S31). 
Despite this marginal effect and the low certainty in the evi-
dence because of risk of bias and inconsistency, the panel 
provided a strong recommendation after consulting with the 
patient representative, who expressed a strong preference for 
close continuous preoperative and postoperative consulta-
tion. The panel considered this practice feasible, requiring 
moderate human and financial resources, and being accept-
able to stakeholders. There was no evidence of any risk for 
the intervention according to the panel’s judgement.
Treatment with ursodeoxycholic acid 
during the weight loss phase following bariatric 
surgery
Treatment with ursodeoxycholic acid could be considered during 
the weight loss phase to prevent gallstones formation
Conditional recommendation
Justification
A meta-analysis of 6 RCTs and two observational studies 
found that ursodeoxycholic acid treatment versus no treat-
ment was associated with lower odds of gallstone formation 
(OR 0.20, 95% CI 0.13 to 0.33) [129]. Due to mixed rand-
omized and observational study design, substantial risk of 
bias and publication bias, certainty in the evidence was very 
low (Supplementary Table S32). Under consideration of the 
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low-risk profile and the low cost of the intervention, the 
panel provided a conditional recommendation, recognizing, 
however, that further research is warranted.
Supplementation of micro and/or micronutrients 
after bariatric surgery
Micro and/or macronutrients supplementation is recommended after 
bariatric surgery according to the type of the procedure and to the 
deficiencies documented during the follow-up
Strong recommendation
Justification
Studies reporting micro and/or macronutrients supplementa-
tion post-surgery are limited. One meta-analysis of 5 RCTs 
and 7 observational studies was identified, which evaluated 
the effect of vitamin D supplementation on preventing Vita-
min D deficiency [130]. Vitamin D deficiency was more 
common in the no supplementation group (OR 3.82, 95% 
CI 1.70 to 8.57) (Supplementary Table S33). Despite the 
sparse evidence, the panel decided to provide a strong rec-
ommendation, as it considered that the anticipated benefits 
outweigh the potential risks of such practice.
Proton‑pump inhibitor (PPI) therapy after bariatric 
surgery for the prevention of marginal ulcers
PPI therapy should be given to patients undergoing bypass proce-
dures for the prevention of marginal ulcers
Strong recommendation
Justification
A meta-analysis of three cohort studies that compared the 
comparative effect of PPIs on marginal ulcers suggested 
beneficial effect of PPI treatment (OR 0.50, 95% CI 0.29 to 
0.90, moderate certainty) (Supplementary Table S34) [131]. 
Under consideration of the risk/benefit ratio, the low cost 
and acceptability of the intervention, the panel provided a 
strong recommendation.
Postoperative nutritional and behavioral advice 
versus standard care
Postoperative nutritional and behavioral advice should be provided 
to patients undergoing bariatric surgery
Strong recommendation
Justification
Evidence supporting the need for postoperative nutritional 
and behavioral counseling is supported by a meta-analysis 
of 6 RCTs [132]. At 12-moth follow-up, the WMD of EWL 
was 11% (95% CI 3% to 19%) in favor of the intervention. 
Certainty of the evidence was, however, very low, due to 
risk of bias, inconsistency and indirectness because of the 
variety of interventions (Supplementary Table S35). Under 
consideration of patient preferences and the anticipated fea-
sibility and moderate resources, the panel supported a strong 
recommendation.
Delaying pregnancy following bariatric surgery 
until after the weight loss phase versus no delay 
on fetal complications
Pregnancy following bariatric surgery should be delayed
during the weight loss phase
Strong recommendation
Justification
Six observational studies reporting fetal outcomes follow-
ing pregnancy after bariatric surgery were identified and a 
meta-analysis comparing early pregnancy versus delayed 
pregnancy was undertaken [133–138]. Delaying pregnancy 
was associated with a trend towards lower odds for admis-
sion in the neonatal intensive care unit (OR 0.73, 95% 0.45 
to 1.18). There were no further substantial findings, how-
ever, certainty was very low across outcomes (Supplemen-
tary Table S36). Despite this sparsity of evidence, the panel 
considered prudent to provide a strong recommendation for 
delaying pregnancy during the weight loss phase to avoid 
fetal complications that may not have been captured by cur-
rent studies.
Topic 7: investigational procedures
Position statement
For duodenal-jejunal bypass sleeves, aspiration devices, gastric 
electrical stimulation, vagal blockade and duodenal mucosal 
resurfacing, the quality of evidence was too low to provide any 
recommendations
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Endoluminal suturing procedures may have a role in the treatment 
of obese patients with BMI below 40 kg/m2
Justification
Evidence was limited for emerging bariatric interventions 
and long-term data were not available. A meta-analysis of 
four RCTs that compared EndoBarrier® with non-surgical 
management was identified [139]. EWL was 36.9% (95% CI 
29% to 45%) at 1-year follow-up (moderate certainty, Sup-
plementary Table S37). EndoBarrier® was reported to be 
associated with 15.7% severe adverse events [139].
One RCT has compared AspireAssist® with lifestyle 
interventions and 1-year follow-up [140]. The WMD of 
EWL was 22% (95% CI 14% to 30%), HbA1c improvement 
was minimal (WMD 0.14%, 95% CI 0% to 0.28%), whereas 
evidence on morbidity was associated with low certainty 
(Supplementary Table S38). No severe complications were 
reported.
Three cohort studies reported on the abiliti® device and 
1-year follow-up [141–143]. EWL ranged from 28.7 to 
49.3%. Few self-limiting adverse events were reported and 
2% severe adverse events. Certainty of the evidence was, 
however, very low.
Two RCTs assessing the effect of vBloc® reported 17% 
and 24% EWL at 1-year follow-up [144, 145]. Two-year 
follow-up suggested sustained weight loss [146, 147]. The 
technical difficulty of the procedure and a high rate of severe 
adverse events are significant drawbacks to this intervention.
One cohort study reported on duodenal mucosal resurfac-
ing, relevant evidence being very low [148]. Two RCTs and 
1 cohort study investigated the effect of the Pose® procedure 
and reported EWL between 16–45% [149–151]. The proce-
dure safety profile seems acceptable, however certainty in 
the evidence was very low.
Five observational studies have addressed the use of 
OverStitch™ [152–156]. The procedure may be considered 
safe, well tolerated and effective with a mean EWL of 50% 
at 1 year. Evidence suggests durability of plications and pro-
gressive weight loss up to 2 years.
Comments
Survey results
The guideline development group aimed to investigate 
whether recommendations and position statements are appli-
cable and can be transferred to individuals’ clinical practice. 
Indeed, one of the AGREE II domains is focused on the 
applicability of the guideline in the practice of target users. 
The rationale was therefore both to assess the clinical merit 
of the recommendations (as an aspect of external validity) 
and to inform the topics of future updates.
A total of 220 professionals involved in the management 
of patients with obesity responded to the 38 survey ques-
tions. The majority of survey participants were surgeons. 
Specifically, bariatric surgeons accounted for 61% of the 
total and 62% of participants worked in high volume bari-
atric centers (defined as > 50 bariatric procedures per year).
The majority of recommendations were considered appli-
cable to participants’ practice. Among those where applica-
bility was judged as low, was the recommendation on routine 
H. pylori eradication. This may be due to the fact that pre-
operative esophagogastroscopy is not considered standard 
preoperative study in many centers. Neutral recommenda-
tions were considered, as expected, to be not applicable by 
a substantial proportion of participants.
Implications for future actions
The present guidelines summarize pertinent evidence in the 
field of bariatric surgery. Despite the advances in the field, 
we have identified several gaps, particularly in the long-term 
reporting of outcomes [90, 91]. Furthermore, we have identi-
fied only two network meta-analyses, which reported several 
outcomes of interest. Considering the variety of treatment 
options, network meta-analysis is the optimal method to 
summarize evidence across interventions in the same meta-
analytical model and is undoubtedly a prosperous field of 
research.
Follow-up reports of emerging procedures, such as 
OAGB, and further, large-scales RCTs on investigational 
procedures, with robust methodology are eagerly awaited. 
As the incidence of obesity increases in societies with a 
high prevalence of psychological disorders, further investi-
gation on the indications for bariatric surgery is warranted. 
Furthermore, obesity is an emerging problem in developing 
countries and, as such, healthcare authorities are called to 
promote health equity by ensuring access to healthcare for 
underprivileged and vulnerable populations.
Conclusions
Evidence from clinical research suggests that bariatric sur-
gery is highly effective in the management of obesity. This 
document summarizes the latest evidence on bariatric sur-
gery. It was developed in compliance with state-of-the art 
methodological principles to reliably appraise evidence, 
hereby facilitating evidence-based clinical decisions and 
informing authoritative actions of policymakers and other 
stakeholders.
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